Ocuphire Initiates ZETA-1 Phase 2 Clinical Trial Investigating APX3330 in Diabetic Retinopathy Apr 8, 2021
Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint Mar 15, 2021
Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update Mar 10, 2021
Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol® Mar 5, 2021
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021 Feb 11, 2021
Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase Jan 20, 2021
Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis Jan 6, 2021
